Movement Alert | CANSINOBIO Falls 5.5% in Regular Trading, Weighed Down by Profit-Taking After Prior Rally

Market Focus10-13 10:28

On October 13, CANSINOBIO fell 5.5% in regular trading, trading at 31.26 HKD, with turnover of 90.44 million HKD.

Prior to this session, the stock experienced a sharp rally in late September driven by positive sentiment around mRNA cancer vaccine prospects, followed by profit-taking after Moderna's sharp decline and a downgrade from Citigroup pressured vaccine names across the market.

In the broader biotechnology sector, peers also traded lower, including AKESO down 3.36%, BEONE MEDICINES down 1.41%, INNOVENT BIO down 2.5%, and METIS TECHBIO-P down 12.83%.

CANSINOBIO is a China-based clinical-stage vaccine company, with products targeting meningitis, pertussis, and pneumonia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment